Trade Schrödinger, Inc. - SDGR CFD

Trading Conditions

• Spread: 0.17
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 23.28
• Open: 23.22
• 1-Year Change: -19.54%
• Day's Range: 23.22 - 24.16

Schrödinger, Inc. Company profile

Schrödinger (SDGR) is a computational platform that facilitates the discovery of molecules for drug development and materials design for biopharmaceutical, academic institutions and government laboratories. 

Founded in 1990, Schrödinger is headquartered in New York. The company has customers and collaborators across more than 70 countries. Its collaborators include Agios Therapeutics, Ajax Therapeutics, Bright Angel Therapeutics, Eli Lilly and Company and Sanofi. 

Schrödinger specialises in oncology, antifungal, fibrosis, inflammatory bowel diseases, metabolic diseases, cardiopulmonary diseases, tuberculosis, neurodegenerative disease and more. 

MALT1 inhibitor is a key regulator of physiological antigen receptor signalling in B cells and T cells and are additive to covalent and non-covalent BTK inhibitors. The company announced US Food and Drug Administration (FDA) clearance of an investigational new drug application for SGR-1505, a MALT1 Inhibitor. 

Schrödinger leverages the software platform to advance its collaborative programmes and its novel therapeutics pipeline includes eight compounds that address unmet medical needs and are currently in the clinical development phase.

Schrödinger, Inc. stock began trading on the NASDAQ in 2020 under the ticker symbol SDGR. 

You can track live SDGR share value and price history at Capital.com.